Visomitin, eye drops 5 ml

Vizomitin has a keratoprotective effect.

Pharmacodynamics

Plastoquinoyldecyltriphenylphosphonium bromide (PDTP) is a derivative of plastoquinone, which is linked to the triphenylphosphine residue through the linker chain (C10). PDTF in low (nanomolar) concentrations exhibits high antioxidant activity.

It also stimulates the process of tear production, epithelization and promotes the increase in tear film stability. According to data of a clinical research, in patients with age-related cataract the preparation protects the eye tissue from oxidative damage by increasing antioxidant activity of the tear and improves visual acuity.

Pharmacokinetics

Pharmacokinetics studies in humans have not been conducted. In preclinical animal studies, distribution of PDTF in organs and tissues occurred within 48 h after intravenous and intragastric administration.

PDTF was found to be present in the highest concentrations in kidney, liver and heart tissues within 1 h of administration. PDTF is relatively rapidly subjected to enzymatic cleavage and covalent binding to proteins.

Indications

Dry eye syndrome, age-related cataracts (to slow the progression of the disease, to delay surgery).

Pharmacological effect

Visomitin has a keratoprotective effect.

Pharmacodynamics

Plastoquinonyldecyltriphenylphosphonium bromide (PDTP) is a derivative of plastoquinone, which is linked to a triphenylphosphine residue through a linker chain (C10). PDTP in low (nanomolar) concentrations exhibits high antioxidant activity.

It also has a stimulating effect on the process of tear production, epithelization, and helps increase the stability of the tear film. According to a clinical study, in patients with age-related cataracts, the drug protects eye tissue from oxidative damage by increasing the antioxidant activity of tears and improves visual acuity.

Pharmacokinetics

Pharmacokinetic studies have not been conducted in humans. In preclinical studies on animals, the distribution of PDTP in organs and tissues occurred within 48 hours after IV and intragastric administration.

PDTP was found to be present in the highest concentrations in the tissues of the kidneys, liver and heart within 1 hour after administration. PDTP undergoes enzymatic degradation and covalent binding to proteins relatively quickly.

Special instructions

Impact on the ability to drive vehicles and machinery.

If short-term blurred vision occurs after using the drug, it is not recommended to drive vehicles or engage in activities that require increased concentration until it is restored.

Active ingredient

Plastoquinonyldecyltriphenylphosphonium bromide

Composition

1 ml eye drops contains:

active ingredient:

plastoquinonyldecyltriphenylphosphonium bromide 0.155 mcg,

excipients:

benzalkonium chloride – 0.1 mg;

hypromellose – 2 mg;

sodium chloride – 9 mg;

sodium dihydrogen phosphate – 0.81 mg;

sodium hydrogen phosphate dodecahydrate – 1.16 mg;

sodium hydroxide 1M solution – to pH 6.3–7.3;

water for injection – up to 1 ml

Pregnancy

Adequate controlled studies have not been conducted in pregnant and breastfeeding women.

It is not recommended to prescribe the drug during pregnancy.

If it is necessary to prescribe during lactation, breastfeeding should be stopped during treatment.

Contraindications

hypersensitivity to the components of the drug;
acute inflammatory diseases of the eye and its appendages;
age up to 18 years.

Side Effects

Allergic reactions.

From the senses: there may be a short-term sensation of burning and stinging in the eyes after instillation.

Interaction

If necessary, can be used simultaneously with other eye drops.

In this case, the break between instillations should be at least 5 minutes.

Storage conditions

In a place protected from light, at a temperature of 2–8 °C

Shelf life

1 year

Manufacturer

Firn M, Russia